Pfizer Gets EC OK for Lorviqua as First-Line Treatment for ALK-Positive Advanced Lung Cancer
January 28 2022 - 10:29AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. on Friday said the European Commission has approved
the expanded use of Lorviqua as monotherapy for adults with
anaplastic lymphoma kinase-positive advanced non-small cell lung
cancer previously not treated with an ALK inhibitor.
The New York drugmaker said the approval is based on results
from a Phase 3 study in which Lorviqua reduced risk of disease
progression or death by 72% in newly diagnosed individuals compared
to the company's Xalkori cancer treatment.
The EC in 2019 granted conditional marketing authorization for
Lorviqua as a monotherapy for adults with ALK-positive advanced
non-small cell lung cancer whose disease has progressed after
alectinib or ceritinib as the first ALK tyrosine kinase inhibitor
therapy, or crizotinib and at least one other ALK tyrosine kinase
inhibitor.
Pfizer markets the drug in the U.S. under the trade name
Lorbrena.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 28, 2022 10:14 ET (15:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024